Malignant transformation in inflammatory bowel disease - Surveillance guide

Digestive Diseases

Volumn 27, Issue 4, 2009, Pages 584-590

  Stallmach, Andreas ^a   Bielecki, Christiane ^a   Schmidt, Carsten ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Colorectal cancer in Crohn's disease; Colorectal cancer in ulcerative colitis; Inflammatory bowel disease, malignant transformation; Surveillance in Crohn's disease; Surveillance programs and guidelines; Surveillance strategies, problems

Indexed keywords

CANCER DIAGNOSIS; CANCER RISK; CARCINOGENESIS; CHROMOENDOSCOPY; CHROMOSOMAL INSTABILITY; COLONOSCOPY; COLORECTAL CANCER; CONFOCAL MICROSCOPY; CROHN DISEASE; DEATH; DISEASE DURATION; DISEASE SURVEILLANCE; EARLY DIAGNOSIS; ENTERITIS; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; MORTALITY; NARROW BAND IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; TUMOR BIOPSY; ULCERATIVE COLITIS;

CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; HUMANS; INFLAMMATORY BOWEL DISEASES; POPULATION SURVEILLANCE; PRACTICE GUIDELINES AS TOPIC;

EID: 70449488914     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000233302     Document Type: Review

References (55)

1. Yeomans FC: Carcinomatous degeneration of rectal adenomas. JAMA 1927; 89: 862.
2. Bargen JA: Chronic ulcerative colitis associated with malignant metaplasia. Arch Surg 1928; 17: 561.
3. Eaden JA, Abrams KR, Mayberry JF: The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-535.
4. Rutter MD, Saunders BP, Wilkinson KH, et al: Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006; 130: 1030-1038.
5. Jess T, Loftus EV Jr, Velayos FS, et al: Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Gastroenterology 2006; 130: 1039-1046.
6. Jess T, Gamborg M, Matzen P, et al: Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 2005; 100: 2724-2729.
7. Ekbom A, Helmick C, Zack M, et al: Ulcerative colitis and colorectal cancer. A population- based study. N Engl J Med 1990; 323: 1228-1233.
8. Heuschen UA, Hinz U, Allemeyer EH, et al: Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology 2001; 120: 841-847.
9. Soetikno RM, Lin OS, Heidenreich PA, et al: Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002; 56: 48-54.
10. Askling J, Dickman PW, Karlen P, et al: Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 2001; 120: 1356-1362.
11. Askling J, Dickman PW, Karlen P, et al: Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study. Lancet 2001; 357: 262-266.
12. Rutter M, Saunders B, Wilkinson K, et al: Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451-459.
13. Gupta RB, Harpaz N, Itzkowitz S, et al: Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007; 133: 1099-1105.
14. Rutter MD, Saunders BP, Wilkinson KH, et al: Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004; 53: 1813-1816.
15. Rubio CA, Befrits R, Ljung T, et al: Colorectal carcinoma in ulcerative colitis is decreasing in Scandinavian countries. Anticancer Res 2001; 21: 2921-2924.
16. Itzkowitz SH, Present DH: Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 314-321.
17. Ekbom A, Helmick C, Zack M, et al: Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 1990; 336: 357-359.
18. Canavan C, Abrams KR, Mayberry J: Metaanalysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther 2006; 23: 1097-1104.
19. Sachar DB: Cancer in Crohn's disease: dispelling the myths. Gut 1994; 35: 1507-1508.
20. Xie J, Itzkowitz SH: Cancer in inflammatory bowel disease. World J Gastroenterol 2008; 14: 378-389.
21. Fearnhead NS, Britton MP, Bodmer WF: The ABC of APC. Hum Mol Genet 2001; 10: 721- 733
22. Morin PJ, Sparks AB, Korinek V, et al: Activation ofß-catenin-TCF signaling in colon cancer by mutations inß-catenin or APC. Science 1997; 275: 1787-1790.
23. Itzkowitz SH, Harpaz N: Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 2004; 126: 1634-1648.
24. Kusaba T, Nakayama T, Yamazumi K, et al: Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol 2005; 58: 833-838.
25. Atreya R, Neurath MF: Signaling molecules: the pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer. Curr Drug Targets 2008; 9: 369-374.
26. Carey R, Jurickova I, Ballard E, et al: Activation of an IL-6:STAT3-dependent transcriptome in pediatric-onset inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 446-457.
27. Pikarsky E, Porat RM, Stein I, et al: NF-κB functions as a tumour promoter in inflammation- associated cancer. Nature 2004; 431: 461-466.
28. Lutgens MW, Vleggaar FP, Schipper ME, et al: High frequency of early colorectal cancer in inflammatory bowel disease. Gut 2008; 57: 1246-1251.
29. Eaden JA, Mayberry JF: Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 2002; 51(suppl 5): V10-V12.
30. Woolrich AJ, DaSilva MD, Korelitz BI: Surveillance in the routine management of ulcerative colitis: the predictive value of lowgrade dysplasia. Gastroenterology 1992; 103: 431-438.
31. Kaltz B, Bokemeyer B, Hoffmann J, et al: Surveillance colonoscopy in ulcerative colitis patients in Germany (in German). Z Gastroenterol 2007; 45: 325-331.
32. Rubin CE, Haggitt RC, Burmer GC, et al: DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992; 103: 1611-1620.
33. Taylor BA, Pemberton JH, Carpenter HA, et al: Dysplasia in chronic ulcerative colitis: implications for colonoscopic surveillance. Dis Colon Rectum 1992; 35: 950-956.
34. Blonski W, Kundu R, Lewis J, et al: Is dysplasia visible during surveillance colonoscopy in patients with ulcerative colitis? Scand J Gastroenterol 2008; 43: 698-703.
35. Kiesslich R, Fritsch J, Holtmann M, et al: Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003; 124: 880-888.
36. Sada M, Igarashi M, Yoshizawa S, et al: Dye spraying and magnifying endoscopy for dysplasia and cancer surveillance in ulcerative colitis. Dis Colon Rectum 2004; 47: 1816-1823.
37. Rutter MD, Saunders BP, Schofield G, et al: Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut 2004; 53: 256-260.
38. Toruner M, Harewood GC, Loftus EV Jr, et al: Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 428-434.
39. Barclay RL, Vicari JJ, Doughty AS, et al: Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. N Engl J Med 2006; 355: 2533-2541.
40. Thomas-Gibson S, Rogers P, Cooper S, et al: Judgement of the quality of bowel preparation at screening flexible sigmoidoscopy is associated with variability in adenoma detection rates. Endoscopy 2006; 38: 456-460.
41. Sachar DB: Cancer in Crohn's disease: dispelling the myths. Gut 1994; 35: 1507-1508.
42. Friedman S, Rubin PH, Bodian C, et al: Screening and surveillance colonoscopy in chronic Crohn's colitis. Gastroenterology 2001; 120: 820-826.
43. Winawer S, Fletcher R, Rex D, et al: Colorectal cancer screening and surveillance: clinical guidelines and rationale - update based on new evidence. Gastroenterology 2003; 124: 544-560.
44. Saunders BP, Brown GJ, Lemann M, et al: Balloon dilation of ileocolonic strictures in Crohn's disease. Endoscopy 2004; 36: 1001-1007.
45. Yamazaki Y, Ribeiro MB, Sachar DB, et al: Malignant colorectal strictures in Crohn's disease. Am J Gastroenterol 1991; 86: 882-885.
46. Connell WR, Sheffield JP, Kamm MA, et al: Lower gastrointestinal malignancy in Crohn's disease. Gut 1994; 35: 347-352.
47. Connell WR, Lennard-Jones JE, Williams CB, et al: Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994; 107: 934-944.
48. Riddell RH, Goldman H, Ransohoff DF, et al: Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983; 14: 931-968.
49. Schlemper RJ, Riddell RH, Kato Y, et al: The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47: 251-255.
50. Kuismanen SA, Holmberg MT, Salovaara R, et al: Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite- unstable colorectal cancers. Am J Pathol 2000; 156: 1773-1779.
51. Bernstein CN, Weinstein WM, Levine DS, et al: Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. Am J Gastroenterol 1995; 90: 2106-2114.
52. Choi PM, Nugent FW, Schoetz DJ Jr, et al: Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 1993; 105: 418-424.
53. Lynch DA, Lobo AJ, Sobala GM, et al: Failure of colonoscopic surveillance in ulcerative colitis. Gut 1993; 34: 1075-1080.
54. Rubin DT, Rothe JA, Hetzel JT, et al: Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc 2007; 65: 998-1004.
55. Obrador A, Ginard D, Barranco L: Review article: colorectal cancer surveillance in ulcerative colitis - what should we be doing? Aliment Pharmacol Ther 2006; 24(suppl 3): 56-63.